Top Stories
Early data published in NEJM points to improved saliva production in six head and neck cancer patients with chronic xerostomia.
The deal brings the Italian drugmaker a potentially first-in-class candidate targeting solid tumours, though its mechanism remains undisclosed.
The IL-1α/1β dual antagonist significantly outperformed placebo on hidradenitis suppurativa-related skin lesion clearance and pain measures.
The C5 inhibitor's accelerated approval is backed by proteinuria reduction in the I CAN trial, with confirmatory data on slowing kidney function decline awaited.
Nearly 2000 AI agents analysed genetic experiments involving millions of mouse brain cells in about 30 minutes, identifying potential disease mechanisms for scientists to investigate.
Conference News
22-Oct-2026 at 10:00 AM EDT, by American Society of Nephrology (ASN)Newswise — Denver, CO (October 22, 2026) — The results of numerous high-impact phase 3 clinical trials that could affect kidney-rela...
Patient data from the Phase 2 study of nipocalimab in Sjögren’s disease identify improvements in most core patient-relevant symptoms, with associated improvements in health-related quality of lifePosi...
- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Ch...
Highlights Include Phase II Data Supporting Clinical Development Expansion for IvonescimabMIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be...
Moderna shares took a tumble Thursday after a third-party purportedly leaked data for its personalised cancer vaccine ahead of a presentation Saturday at the European Society of Clinical Oncology (ESM...
